RxDoctor Payments Data

Keri Livingstone

Internal Medicine · Miami Shores, FLNPI 1316902455

Payments from drug & device makers

$661in general payments, 2019–2025

Across 35 payments — averaging $18.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$179
  • Novo Nordisk$161
  • Pfizer$142
  • GSK$42
  • Johnson & Johnson$41
  • AbbVie$36
  • plus $59 from 3 others

What the payments were for

  • Food & beverage$661100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca9$179
Novo Nordisk9$161
Pfizer8$142
GSK2$42
Johnson & Johnson2$41
AbbVie(2 entities)2$36
Exact Sciences1$26
Gilead1$17
Amarin Pharma, Inc.1$17

How this compares

$661 in reported general payments places this provider in the 60th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$45,329
Medicare patients
100
Services billed
821

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$51,967
WegovySemaglutide11$16,373
MounjaroTirzepatide18$14,481
Janumet XrSitagliptin Phos/Metformin Hcl15$14,171
ArexvyRsvpref3 Antigen/As01e/Pf43$12,935
MyrbetriqMirabegron12$5,545
ShingrixVaricella-Zoster Ge/As01b/Pf14$3,029
Esomeprazole Magnesium20$2,178
Rosuvastatin Calcium108$1,644
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine14$1,409
Estradiol19$1,330
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf15$1,026
Atorvastatin Calcium104$793
Amlodipine Besylate59$672
Metoprolol Succinate32$624

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$161$68,34051 claims
GSKArexvy, Shingrix$42$15,96357 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami Shores

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →